GH Research PLCGHRS stock score: 42/100

$18.56 · +1.70% · Scored Nov 19, 2026

Technical
44
Fundamental
41
News
50

The reading

GH Research (GHRS) scores 42 out of 100, which reads weak, higher than 28% of Healthcare stocks and 26% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 41, technicals 44.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (Quarterly) at 1 weighs the most against it.

On the daily chart, trend-following indicators average 27 and contrarian oscillators 64 — a split worth reading before trusting the technical total.

News sentiment is neutral at 50; it is shown, not counted in the composite.

Since Aug 23, 2026 the composite has ranged from 38 to 52, and it is down 6 points over the period.

About GH Research

GH Research (GHRS) is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that develops treatments for depression based on mebufotenin, also known as 5-MeO-DMT, a fast-acting psychedelic compound. Its lead candidate, GH001, is an inhaled form of mebufotenin given in an individualized dosing regimen within a single day, with the aim of producing rapid and lasting relief in patients with treatment-resistant depression without long in-clinic sessions. In a mid-stage trial, GH001 significantly reduced depression scores compared with placebo within days. After the U.S. Food and Drug Administration lifted a clinical hold on its U.S. application, the company is preparing a global late-stage program. GH Research is also developing GH002, an intravenous formulation of mebufotenin. It has no product revenue and funds development from cash raised from investors.

GH Research competes with Johnson & Johnson’s Spravato and with other companies developing psychedelic-based treatments for depression, including COMPASS Pathways, AtaiBeckley and MindMed. Its edge rests on a short-acting compound that may fit more easily into clinical practice than longer-acting psychedelics and on strong mid-stage efficacy data. Investors who follow GHRS stock tend to watch the start and progress of its late-stage trials. Interactions with the FDA and other regulators are closely followed. Safety findings, cash runway and the progress of competing psychedelic therapies are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward GHRS’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

41

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

26 weighted scorers; 13 had no data today and are left out rather than counted as zero.

Technical · daily

31

Pulling it up

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.

  • The price change over the last 52 weeks.

Holding it back

  • Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.

  • Simple Moving Average (100-period) provides a longer-term perspective on price trends.

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
50

Technical score by timeframe

ChartScoreWeight
Hourly501
Daily313
Weekly432
Monthly602

Composite score, last 90 days

05010042Aug 23, 2026Nov 19, 2026Aug 23, 2026: 48Aug 24, 2026: 48Aug 25, 2026: 50Aug 26, 2026: 50Aug 27, 2026: 49Aug 28, 2026: 48Aug 29, 2026: 49Aug 30, 2026: 49Aug 31, 2026: 47Sep 1, 2026: 49Sep 2, 2026: 50Sep 4, 2026: 49Sep 5, 2026: 49Sep 6, 2026: 50Sep 7, 2026: 50Sep 8, 2026: 50Sep 9, 2026: 47Sep 10, 2026: 48Sep 11, 2026: 47Sep 12, 2026: 47Sep 13, 2026: 47Sep 14, 2026: 49Sep 15, 2026: 49Sep 16, 2026: 49Sep 17, 2026: 52Sep 18, 2026: 50Sep 19, 2026: 50Sep 20, 2026: 50Sep 21, 2026: 51Sep 22, 2026: 49Sep 23, 2026: 48Sep 24, 2026: 46Sep 25, 2026: 45Sep 26, 2026: 45Sep 27, 2026: 45Sep 28, 2026: 45Sep 29, 2026: 47Sep 30, 2026: 45Oct 1, 2026: 44Oct 2, 2026: 45Oct 3, 2026: 45Oct 4, 2026: 45Oct 5, 2026: 44Oct 6, 2026: 43Oct 7, 2026: 43Oct 8, 2026: 43Oct 9, 2026: 43Oct 10, 2026: 43Oct 11, 2026: 43Oct 12, 2026: 42Oct 13, 2026: 41Oct 14, 2026: 40Oct 15, 2026: 41Oct 16, 2026: 40Oct 17, 2026: 40Oct 18, 2026: 40Oct 19, 2026: 41Oct 20, 2026: 41Oct 21, 2026: 42Oct 22, 2026: 41Oct 23, 2026: 40Oct 24, 2026: 40Oct 25, 2026: 40Oct 26, 2026: 42Oct 27, 2026: 43Oct 29, 2026: 44Oct 30, 2026: 45Nov 1, 2026: 45Nov 2, 2026: 45Nov 3, 2026: 45Nov 4, 2026: 43Nov 5, 2026: 40Nov 6, 2026: 39Nov 7, 2026: 41Nov 10, 2026: 43Nov 11, 2026: 42Nov 12, 2026: 38Nov 13, 2026: 41Nov 14, 2026: 41Nov 15, 2026: 41Nov 18, 2026: 41Nov 19, 2026: 42
Show the daily numbers
DateComposite
Nov 19, 202642
Nov 18, 202641
Nov 15, 202641
Nov 14, 202641
Nov 13, 202641
Nov 12, 202638
Nov 11, 202642
Nov 10, 202643
Nov 7, 202641
Nov 6, 202639
Nov 5, 202640
Nov 4, 202643
Nov 3, 202645
Nov 2, 202645
Nov 1, 202645
Oct 30, 202645
Oct 29, 202644
Oct 27, 202643
Oct 26, 202642
Oct 25, 202640
Oct 24, 202640
Oct 23, 202640
Oct 22, 202641
Oct 21, 202642
Oct 20, 202641
Oct 19, 202641
Oct 18, 202640
Oct 17, 202640
Oct 16, 202640
Oct 15, 202641
Oct 14, 202640
Oct 13, 202641
Oct 12, 202642
Oct 11, 202643
Oct 10, 202643
Oct 9, 202643
Oct 8, 202643
Oct 7, 202643
Oct 6, 202643
Oct 5, 202644
Oct 4, 202645
Oct 3, 202645
Oct 2, 202645
Oct 1, 202644
Sep 30, 202645
Sep 29, 202647
Sep 28, 202645
Sep 27, 202645
Sep 26, 202645
Sep 25, 202645
Sep 24, 202646
Sep 23, 202648
Sep 22, 202649
Sep 21, 202651
Sep 20, 202650
Sep 19, 202650
Sep 18, 202650
Sep 17, 202652
Sep 16, 202649
Sep 15, 202649
Sep 14, 202649
Sep 13, 202647
Sep 12, 202647
Sep 11, 202647
Sep 10, 202648
Sep 9, 202647
Sep 8, 202650
Sep 7, 202650
Sep 6, 202650
Sep 5, 202649
Sep 4, 202649
Sep 2, 202650
Sep 1, 202649
Aug 31, 202647
Aug 30, 202649
Aug 29, 202649
Aug 28, 202648
Aug 27, 202649
Aug 26, 202650
Aug 25, 202650
Aug 24, 202648
Aug 23, 202648

Key facts

Market cap
$1.3B
Sector
Healthcare
Industry
Biotechnology
Beta
1.32
Risk grade (1–10)
—
Next earnings
Nov 13, 2026

Questions

What is GHRS's stock rating today?

GHRS scores 42/100 (Weak) as of Nov 19, 2026: technical 44, fundamental 41, and news sentiment 50, which is shown but not counted. Scores are recomputed every night.

What does GH Research do?

GH Research (GHRS) is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that develops treatments for depression based on mebufotenin, also known as 5-MeO-DMT, a fast-acting psychedelic compound. Its lead candidate, GH001, is an inhaled form of mebufotenin given in an individualized dosing regimen within a single day, with the aim of producing rapid and lasting relief in patients with treatment-resistant depression without long in-clinic sessions.

Is GHRS stock a buy?

The score is not a buy or sell recommendation. A 42 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the GHRS score calculated?

88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

GHRS stock score

HTML

<a href="https://stocksscores.com/stocks/ghrs/"><img src="https://stocksscores.com/stocks/ghrs/badge.svg" alt="GHRS stock score" height="20"></a>

Markdown

[![GHRS stock score](https://stocksscores.com/stocks/ghrs/badge.svg)](https://stocksscores.com/stocks/ghrs/)